ConductScience.org, home

Comparison · NCT00221338-4468cf9b

Gabapentin vs Placebo: Incidence of Postoperative Delirium by Study Group

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Gabapentin vs Placebo: Incidence of Postoperative Delirium by Study Group. Trial comparisons, record NCT00221338-4468cf9b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00221338-4468cf9b

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.240.1980.287wilson
Risk in group 20.2070.1680.253wilson
Risk difference, group 1 minus group 20.0325-0.02940.0941newcombe hybrid score
Risk ratio, group 1 over group 21.160.8761.53log
Odds ratio, group 1 over group 21.210.8441.72log
Number needed to treat, for one more participant with the outcome on Gabapentin than on Placebo30.8from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Gabapentin
Double blind, placebo controlled~Gabapentin: This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days
84350OG000
Group 2Placebo
Double blind~Gabapentin: This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days
72347OG001

Outcome

Type
PRIMARY
Title
Incidence of Postoperative Delirium by Study Group
Description
Number of subjects who developed postoperative delirium, as measured by the Confusion Assessment Method, a validated tool for assessing delirium based on DSM-III-R, on any of the first three postoperative days.
Time frame
postoperative days 1, 2 and 3
Population

Source ClinicalTrials.gov

Trial

Title
Clinical Trial of Gabapentin to Decrease Postoperative Delirium and Pain
NCT number
NCT00221338
Phases
PHASE3
Conditions
Postoperative Delirium, Postoperative Pain, Opioid Use, Hospital Length of Stay
Interventions
Gabapentin
Lead sponsor
University of California, San Francisco
Results first posted
2020-09-10

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00221338-4468cf9b